SENS Senseonics Holdings Inc

$SENS I was in line to pickup a prescription yesterday and the young lady in front of me was nearly in tears saying that she had just purchased a new supply of G7s and the one she put on that morning had already fallen off and was wanting a replacement. The pharmacy tech looked at her with sympathetic eyes and informed her they could not replace it, but offered her finger sticks which she had no choice but take because her insurance wouldn’t replace the G7. I was hesitant in approaching her and her husband to give them an Eversense pitch but I did and gave them an Endo a block away that is a certified inserter. They both seemed excited. 🤷‍♂️Don’t know if I got the sale, but they took down the Website and thanked me. Tim should pay his shareholders commission 😎

$SENS just scheduled my 2nd replacement for 12/17 same provider as last year, felt very comfortable with them so going back. Another year with absolutely no issues. One great tell for me is that the two reps I've communicated with for the past two years are still with the company and even more enthusiastic about it's future. At this point you would have to hold a gun to my head for me to go back to the Libre. So far it's been a phenomenal product/CGM but not a great stock, I'm in the camp that the stock will eventually be valued accordingly. Will be adding here. 😉

$SENS last 2 update of Eversense 365 download , we can see that download number is increasing, this is only for the Android market, iOS is not included.

$SENS Just a reminder from last call Active prescribers +130% Record shipments — highest ever DTC conversion improving Eon Care ~40% of U.S. insertions 90% switchers from competing CGMs U.S. revenue +150% 59% clean gross margin Guidance raised to $62–66M Gemini: study complete by YE 2026; 510(k) Q1 2027 Freedom: first-in-human H2 2026

$SENS This is great, so far, for LTH's. Would love to establish true support at $8. Pullback was expected, probably by many LTH's. Practical support held so far. Stand by my analysis, that after Q3 earnings call, there is a 70% chance intermediate confirmation of the GC will occur in Q4 @ $10.20. From my perspective only a weekly close, counts, not a daily close spike. We shall see. I bet on it with a 1000 share DCA buy at $8.40. Yea could have bought lower but put the order in at $10.20 knowing practical support was a $1 lower. Matters little. Gaps fill at equal proportion up or down. You can believe, as some posters stated, that the gap up from $5 must fill. The odds are strongly in favor of the gap down from $10.20 will fill & that gap up from $5 is history and will never fill.

$SENS Could $SENS hit $40 by Q1 2027? Many will dismiss it, but the momentum is real: revenue +120%, U.S. sales +150%, prescribers +130%, record shipments, ~90% of new patients switching from other CGMs, Eon Care scaling fast, Europe ramping in H2, guidance raised, GEMINI study completion targeted by year-end with a Q1 2027 510(k), and more pump partners ahead. Patience could be rewarded.

$SENS FWIW & FYI: I just listened to part of the Senate hearings for the potential confirmation of Heidi Overton, MD, PhD (& Surgeon) as the new FDA Commissioner. Dr. Overton stated she has "Adult Onset Type One Diabetes". If confirmed the Diabetic community will now have someone who is a T1D that obviously understands the challenges that all Diabetics face. Hopefully she will expedite approvals of new meds and products such as the now available E365 - then Gemini & Freedom - and related AID pump systems to assist in everyday living for this community. Best wishes for her health & confirmation. GLTA Longs...

$SENS latest update from our German Eversense 365 user, the accuracy is really out of this world

$SENS Guidance will be raised to at least 70-75M+. Remember, they never really factored in European sales into their guidance and if they did, really conservatively. I think EU sales may be taking off soon IMO. Them Germans do like the highest level and precision technology, which Eversense 365 brings to the table.

$SENS Still up over 70% on the three month, she needed a little breather and these bad market days are perfect to do it. I would ignore Barclays. They appear to have a short position that they need to get out of. Next earnings report is coming, and they know 3 time's a trend! If it hits, they'll lose their azzes on those positions.

$SENS we need to strike a partnership with $TNDM to increase possible insertion base. And better insurance coverage is needed.

$SENS my only regret is not having more money to add here, been focusing on a different ticker. still bullish hoping i can get more at these prices by the time i have some liquidity.

$SENS I don’t quite get it. Sales have begun in the European markets, yet there hasn’t been a single word or even a tweet from the company. Until there’s some positive news and volume, it’s just treading water.

$SENS we mooning next week, hope to see a ramp to earnings. All just noise, nothing has changed the last 2 weeks, no reason for the

$SENS SENS is undervalued! Deservedly so. E-level financial mismanagement. The "Street" has not bought in yet. CEO's Wallstreet incompetence is deafening. Raised capital multiple times at near SP lows. Lack of foresight doubled dilution unnecessarily. Total incompetence. Yet, the tech is by far the best in the world. Nothing else is close. The tech will win! With demonstrated sales growth, excellent GP, & a strong balance sheet; SENS should have a market cap at least 10 X sales & arguably 15 X sales. Q3 results will be the beginning of an assured LT bull run.

$SENS 27k vol 30 mins in, no one is selling shorts, gotta cover. gonna hit 12 whether you like it or not, just short it again once it gets there.

$SENS So based on f.. Barclays coverage, all the progress and revenue grow has zero effect on SP positively with their price target of 10$. Its completely a bs coverage. Smells like coverage for their shorting plan.

$SENS That wasn't exactly the close that I was hoping for, but it's green. Green is good!

$SENS they don't need to. Senseonics just needs to focus on executing sales all across the board provide an update during quarterly calls. Shorts days are numbered once they announce increased guidance for 2027 and another quarter beat showing 100%+ year over year growth.

$SENS Something needs to put an end to this wave of declines already—just when we’d finally climbed, we’re losing altitude again?!